Drug intelligence / Profile preview

[203Pb]Pb-AB102

Development stage
Unknown
Lead developer
ARTBIO
Modality
Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides
Administration
Intravenous
01

Overview

[203Pb]Pb-AB102 is a radiopharmaceutical imaging agent developed by ARTBIO for the detection and characterization of solid tumors expressing integrin αvβ6. It consists of a targeting ligand, AB102, chelated to the radioisotope lead-203 ([203Pb]), which emits gamma radiation suitable for Single Photon Emission Computed Tomography (SPECT) imaging. AB102 specifically targets integrin αvβ6, a cell surface receptor upregulated in several aggressive cancers, including triple-negative breast cancer (TNBC) and squamous cell carcinoma (SCC), while showing minimal expression in healthy tissues. This agent serves as a diagnostic companion (theranostic pair) to [212Pb]Pb-AB102, an alpha-emitting therapeutic candidate, allowing for patient selection and biodistribution monitoring in clinical trials.

Other names
Lead-203 AB102Lead203 AB102Lead 203 AB102203Pb-AB102
02

Targets

αVβ6 (Integrin αVβ6)

Beyond the preview

Go deeper on [203Pb]Pb-AB102.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on [203Pb]Pb-AB102.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call